Related Experiment Video
Updated: May 12, 2026

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Probiotic administration in congenital heart disease: a pilot study
C L Ellis1, N A Bokulich, K M Kalanetra
1Department of Internal Medicine, University of California Davis, Davis, CA 95817, USA.
Insights
Probiotic Bifidobacterium longum ssp. infantis did not alter the gut microbiota in infants with congenital heart disease. While some plasma cytokines showed transient changes, the overall impact was inconsistent, suggesting further research is needed.
Area of Science:
- Neonatal immunology
- Microbiome research
- Pediatric cardiology
Background:
- Congenital heart disease (CHD) in infants is linked to gut dysbiosis.
- The gut microbiome plays a crucial role in immune system development.
- Understanding microbial and immune alterations in CHD is vital for therapeutic interventions.
Purpose of the Study:
- To assess the effect of probiotic Bifidobacterium longum ssp. infantis (B. infantis) on fecal microbiota composition in neonates with CHD.
- To evaluate the impact of B. infantis supplementation on plasma cytokine profiles in these infants.
Main Methods:
- A randomized, placebo-controlled trial involving 16 infants with CHD.
- Infants received either B. infantis or placebo for 8 weeks.
- Fecal microbial composition and weekly plasma cytokine levels (IL-10, IFN-γ, IL-1β) were analyzed.
Main Results:
- Infants with CHD exhibited altered fecal microbiota compared to healthy controls, but B. infantis did not significantly change microbial composition in CHD infants.
- Plasma levels of interleukin-10 (IL-10), interferon-gamma (IFN-γ), and interleukin-1beta (IL-1β) were transiently elevated in the probiotic group.
- No significant differences in fecal microbiota were observed between the probiotic and placebo groups.
Conclusions:
- Infants with CHD experience gut dysbiosis.
- Probiotic B. infantis supplementation did not significantly alter the fecal microbiota in neonates with CHD.
- Observed changes in plasma cytokines were inconsistent, indicating a limited impact of the probiotic on the measured immune markers.
Objective:
To investigate the impact of probiotic Bifidobacterium longum ssp. infantis on the fecal microbiota and plasma cytokines in neonates with congenital heart disease.
Study Design:
Sixteen infants with congenital heart disease were randomly assigned to receive either B. infantis (4.2 × 10(9) colony-forming units two times daily) or placebo for 8 weeks. Stool specimens from enrolled infants and from six term infants without heart disease were analyzed for microbial composition. Plasma cytokines were analyzed weekly in the infants with heart disease.
Results:
Healthy control infants had increased total bacteria, total Bacteroidetes and total bifidobacteria compared to the infants with heart disease, but there were no significant differences between the placebo and probiotic groups. Plasma interleukin (IL)10, interferon (IFN)γ and IL1β levels were transiently higher in the probiotic group.
Conclusion:
Congenital heart disease in infants is associated with dysbiosis. Probiotic B. infantis did not significantly alter the fecal microbiota. Alterations in plasma cytokines were found to be inconsistent.
Related Concept Videos
Probiotics
Development of the Oral Microbiota
Development of Human Microbiota
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
